208340 fundamentals
Key facts
Market capitalization—
Founded—
CEO—
Website—
About
PharmAbcine Inc. engages in the development of human therapeutic monoclonal antibody (mAb) for the treatment of cancer and inflammatory diseases. It focuses primarily on the out-licensing of candidate therapeutics and clinical applications. The company develops TTAC0001, a human anti-angiogenic mAb against VEGFR-2(KDR); and dual specific antibody technologies, including DIG-body and PIG-body for therapeutic use. The company was founded by Jin-San Yoo and Sang-Hoon Lee in September 3, 2008 and is headquartered in Daejeon, South Korea.
Valuation
Fundamental metrics to determine fair value of the stock
Growth and Profitability
Company’s recent performance and margins
Dividends
Dividend yield, history and sustainability
208340 does not pay dividends
The company has not previously paid dividends and at the moment there is no information about whether it is going to pay them in the future
Financial health
Financial position and solvency of the company